Literature DB >> 17425730

Magnetization transfer MRI in multiple sclerosis.

Massimo Filippi1, Federica Agosta.   

Abstract

In multiple sclerosis (MS), conventional magnetic resonance imaging (cMRI) has proved to be sensitive for detecting lesions and their changes over time. However, cMRI is not able to characterize and quantify the tissue damage within and outside such lesions. Magnetization transfer (MT) MRI is a quantitative technique with the potential to overcome this limitation and, as a consequence, to provide additional information about the nature and the extent of tissue damage associated to this disease. During the last 10 years, MT MRI indeed has allowed us to quantify the structural changes occurring within and outside lesions visible on cMRI scans, thus providing a more accurate in vivo picture of the heterogeneity of MS and, as a consequence, improving our ability to monitor the evolution of the disease. The application of MT MRI to the study of MS has contributed to change our understanding of how MS causes irreversible disability by showing that MS is more than an inflammatory-demyelinating condition of the white matter of the central nervous system.

Entities:  

Mesh:

Year:  2007        PMID: 17425730     DOI: 10.1111/j.1552-6569.2007.00132.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  25 in total

1.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

Review 3.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

4.  Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.

Authors:  Michael Amann; Athina Papadopoulou; Michaela Andelova; Stefano Magon; Nicole Mueller-Lenke; Yvonne Naegelin; Christoph Stippich; Ernst Wilhelm Radue; Oliver Bieri; Ludwig Kappos; Till Sprenger
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

5.  Chronic T2 Lesions in Multiple Sclerosis are Heterogeneous Regarding Phase MR Imaging.

Authors:  S Siemonsen; K L Young; M Bester; J Sedlacik; C Heesen; J Fiehler; J-P Stellmann
Journal:  Clin Neuroradiol       Date:  2015-04-18       Impact factor: 3.649

6.  Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2011-08-24       Impact factor: 4.849

Review 7.  Progressive multiple sclerosis and gray matter pathology: an MRI perspective.

Authors:  Matilde Inglese; Niels Oesingmann; Patrizia Casaccia; Lazar Fleysher
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

8.  Immunopathogenesis of multiple sclerosis.

Authors:  Michael K Racke
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

9.  Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.

Authors:  Richard G Abramson; Lori R Arlinghaus; Jared A Weis; Xia Li; Adrienne N Dula; Eduard Y Chekmenev; Seth A Smith; Michael I Miga; Vandana G Abramson; Thomas E Yankeelov
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-10

10.  Magnetization transfer imaging in 'premanifest' Huntington's disease.

Authors:  Caroline K Jurgens; Reineke Bos; Jasper Luyendijk; Marie-Noëlle W Witjes-Ané; Jeroen van der Grond; Huub A M Middelkoop; Raymund A C Roos
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.